Bradmer announces 2008 third quarter operational and financi...( TSX: BMR TORONTO Nov. 10 / Bra...),Health

TSX: BMR

TORONTO, Nov. 10 /PRNewswire-FirstCall/ - Bradmer Pharmaceuticals Inc., a clinical oncology company specializing in the development and commercialization of cancer therapies, today announced its 2008 third quarter operational and financial results.

Operational Highlights

During the three months ended September 30, 2008 and the period subsequent to this date, the Company achieved the following milestones related to its operations and its lead drug, Neuradiab(TM), which is being studied in the Phase III GLASS-ART(TM) Trial:

- Maintained budgetary control and reduced quarterly spending;

- Signed clinical study contracts with nine of the initial 16 sites

under active consideration and activated an initial cohort of five

sites, while advancing a pipeline of additional sites in the US

through the contractual, training and regulatory process;

- Initiated dialog with Health Canada for study expansion into key

Canadian sites with the support of the Canadian Brain Cancer

consortium;

- Enrolled the first group of patients in the GLASS-ART Trial and

successfully dosed patients with Neuradiab at multiple sites;

- Announced new data from the most recent Phase II trial indicating that

the mean time to progression free survival was 77 weeks, which

compares favorably with other published results in newly diagnosed

GBM;

- Evaluated a series of technical steps that may allow a two week

extension of the shelf life of Neuradiab beyond the current six-day

specification; and

- Appointed Dr. Donald Kufe, Professor of Medicine, Harvard Medical

School and Director, Experimental Therapeutics Program, Dana-

Farber/Harvard Cancer Center and Charles James Lilly, CA, a senior

partner with a public accounting firm, to the Board of Directors of

the Company.

"The treat
'/>"/>